Published in J Infect Dis on May 01, 1992
Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care (2006) 3.19
Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar typhimurium infection despite attenuated cytokine response. Infect Immun (2001) 1.40
Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury : possible connection to an interleukin-6-dependent pathway. Am J Pathol (2000) 1.21
Glomerular inflammation induces resistance to tubular injury in the rat. A novel form of acquired, heme oxygenase-dependent resistance to renal injury. J Clin Invest (1996) 1.20
Estrogen: a novel therapeutic adjunct for the treatment of trauma-hemorrhage-induced immunological alterations. Mol Med (2008) 1.11
Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect Immun (2000) 1.10
Attenuation of fever and release of cytokines after repeated injections of lipopolysaccharide in guinea-pigs. J Physiol (1994) 0.93
Experimental colitis attenuates development of toxin-induced cholangitis in rats. Dig Dis Sci (2002) 0.92
Structural and serological specificities of Pasteurella haemolytica lipopolysaccharides. Infect Immun (1993) 0.85
Endotoxin tolerance variation over 24 h during porcine endotoxemia: association with changes in circulation and organ dysfunction. PLoS One (2013) 0.80
Rectal administration of lipopolysaccharide and ovalbumin ameliorates acute murine colitis. Dig Dis Sci (2011) 0.79
Endotoxin, cellular immune dysfunction and acute pancreatitis. Ann R Coll Surg Engl (1996) 0.79
Histone preconditioning protects against obstructive jaundice-induced liver injury in rats. Exp Ther Med (2014) 0.77
Lactobacillus plantarum CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response. Eur J Nutr (2014) 0.77
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med (1989) 4.66
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet (1987) 4.18
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A (1989) 3.88
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A (1992) 3.61
An overview of mortality risk prediction in sepsis. Crit Care Med (1995) 3.37
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A (1991) 3.21
Sepsis syndromes: understanding the role of innate and acquired immunity. Shock (2001) 3.11
Segment-oriented hepatic resection in the management of malignant neoplasms of the liver. J Am Coll Surg (1998) 3.04
Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol (1989) 3.03
Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg (1998) 2.97
Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol (1997) 2.86
Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg (1998) 2.81
Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 (1999) 2.81
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer (2008) 2.63
Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg (2000) 2.60
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg (1999) 2.57
Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol (2000) 2.48
Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg (1996) 2.39
Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis (1997) 2.39
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19
Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol (1997) 2.15
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol (2008) 2.12
The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest (1990) 2.08
IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol (1991) 2.03
One hundred consecutive hepatic resections. Blood loss, transfusion, and operative technique. Arch Surg (1994) 2.03
Inflammatory cytokines and cell response in surgery. Surgery (2000) 2.02
Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest (1996) 1.99
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol (1989) 1.99
Management of 155 patients with benign liver tumours. Br J Surg (2001) 1.97
Current estimates from the National Health Interview Survey, 1992. Vital Health Stat 10 (1994) 1.95
Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 10 (1998) 1.95
Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol (1995) 1.94
Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis (1988) 1.94
Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis (1996) 1.88
Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg (2000) 1.85
Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J (1989) 1.82
Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans. Ann Surg (1989) 1.79
Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol (1992) 1.78
Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol (1999) 1.75
Results of hepatic resection for sarcoma metastatic to liver. Ann Surg (2001) 1.75
Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J (2001) 1.73
Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol (1993) 1.73
Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality. J Am Coll Surg (2001) 1.69
Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery (1997) 1.68
Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol (2001) 1.66
The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair. Crit Care Med (2000) 1.65
Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J (1999) 1.64
Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis (1997) 1.63
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol (2003) 1.63
Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem (2000) 1.59
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest (1992) 1.58
A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer (2001) 1.57
Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol (2000) 1.57
A prospective analysis of staging laparoscopy in patients with primary and secondary hepatobiliary malignancies. J Gastrointest Surg (2000) 1.57
Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol (1990) 1.55
Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery (2001) 1.55
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Cytokine signaling--regulation of the immune response in normal and critically ill states. Crit Care Med (2000) 1.50
Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet (1990) 1.50
Protein dynamics during refeeding of protein-depleted rats: effects of increasing amino acid intake by TPN or enteral continuous feeding. J Nutr (1984) 1.50
Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc Natl Acad Sci U S A (2001) 1.49
Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med (1986) 1.49
Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A (1990) 1.47
Effects of intravenous IL-8 administration in nonhuman primates. J Immunol (1992) 1.44
Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res (1991) 1.44
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer (2008) 1.43